ImmuCell Corp Files 8-K Report
Ticker: ICCC · Form: 8-K · Filed: Jun 25, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financial-update
Related Tickers: ICEL
TL;DR
ImmuCell filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On June 25, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that ImmuCell Corporation is providing updates to the SEC, which could contain important information for investors regarding the company's financial health or significant operational developments.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information that inherently suggests high risk.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- June 25, 2025 (date) — Date of Report
- 56 Evergreen Drive Portland, Maine 04103 (address) — Principal executive offices
FAQ
What specific "Other Events" are being reported by ImmuCell Corporation in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported, only that this item is included in the filing.
Are there any new financial statements or exhibits being filed with this 8-K?
Yes, the filing indicates "Financial Statements and Exhibits" as an item information, suggesting new or updated financial documents are being submitted.
What is the principal executive office address for ImmuCell Corporation?
The principal executive offices are located at 56 Evergreen Drive, Portland, Maine 04103.
When was this 8-K report filed?
The report was filed on June 25, 2025.
What is the SEC Act under which this report is filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding IMMUCELL CORP /DE/ (ICCC).